Chimeric Antibody Engineering Against Bacillus anthracis Lethal Toxin: Neutralization Efficacy and Mechanism of Action
Toxins · 09.01.2026 · 18 (1) · 31
DOI: 10.3390/toxins18010031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, online erschienen am 09.01.2026. Verfasst von Olga V Kalmantaeva und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Research Center for Applied Microbiology and Biotechnology, 142279 Obolensk, Russia. Hauptthemen laut MEDLINE: Bacterial Toxins, Antigens, Bacterial, Antibodies, Monoclonal, Bacillus anthracis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Ministry of Education and Science.
Abstract (Originalsprache)
Bacillus anthracis has three main virulence factors: an extracellular capsule and two binary toxins (lethal toxin—consists of a lethal factor and a protective antigen, and edema toxin—consists of an edema factor and a protective antigen). In the Russian Federation, the epidemiological situation regarding anthrax infection remains unfavorable. In the late stages of an anthrax infection, antibiotic therapy becomes ineffective and the patient dies within 24 h as a large amount of lethal toxin accumulates in the patient’s blood. Antibodies capable of neutralising lethal toxin (LT) can be an effective treatment for these patients. The objective of the study was to construct a chimeric monoclonal antibody targeting the protective antigen of the LT and to elucidate its mechanism of toxin neutralization. In this work, a chimeric monoclonal antibody (xi1E10) directed against the protective antigen was successfully produced. Both in vitro and in vivo experiments demonstrated the capacity of xi1E10 to neutralize lethal toxin. Confocal microscopy revealed that xi1E10 effectively suppresses the formation of a functional pore, thereby blocking the translocation of the lethal factor into the cytosol. These findings indicate that the monoclonal antibody xi1E10 represents a promising candidate for the development of a therapeutic drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Research Center for Applied Microbiology and Biotechnology, 142279 Obolensk, Russia.
ORCID-Profile: Olga V Kalmantaeva, Alena K Ryabko, Tatyana I Kombarova
Förderung
- Russian Ministry of Education and Science
Zitieren
APA
Kalmantaeva, O. V., Marin, M. A., Ershova, A. A., Ryabko, A. K., Romanenko, Y. O., Kombarova, T. I., Dyatlov, I. A., & Firstova, V. V. (2026). Chimeric Antibody Engineering Against Bacillus anthracis Lethal Toxin: Neutralization Efficacy and Mechanism of Action. Toxins, 18(1), 31. https://doi.org/10.3390/toxins18010031
Vancouver
Kalmantaeva OV, Marin MA, Ershova AA, Ryabko AK, Romanenko YO, Kombarova TI, et al. Chimeric Antibody Engineering Against Bacillus anthracis Lethal Toxin: Neutralization Efficacy and Mechanism of Action. Toxins. 2026;18(1):31. doi:10.3390/toxins18010031
BibTeX
@article{Kalmantaeva2026,
author = {Kalmantaeva, Olga V and Marin, Maksim A and Ershova, Anastasia A and Ryabko, Alena K and Romanenko, Yana O and Kombarova, Tatyana I and Dyatlov, Ivan A and Firstova, Victoria V},
title = {Chimeric Antibody Engineering Against Bacillus anthracis Lethal Toxin: Neutralization Efficacy and Mechanism of Action},
journal = {Toxins},
year = {2026},
volume = {18},
number = {1},
pages = {31},
doi = {10.3390/toxins18010031}
}
EUVIMED